Conjugate vaccines will lead vaccines sales through 2035 with 24.7% share of the vaccine type segment in 2025. Human use holds 68.2% share of the application segment in 2025. The market was valued at USD 54.50 billion in 2025 and is projected to reach USD 111.3 billion by 2035.